

Peter R. Breggin, M.D.
101 East State Street, No. 112
Ithaca, New York 14850
www.breggin.com

Phone 607 272 5328

Fax 607 272 5329

RESUME SUMMARY

I. BACKGROUND HIGHLIGHTS:

Harvard College (Cambridge) (1954-58):

Graduated with Honors in Social Relations.

Directed Harvard-Radcliffe Mental Hospital Volunteer Program.

Research grants from Harvard Medical School and the National Institute of Mental Health (NIMH).

Co-authored 1st professional book, College Students in a Mental Hospital (1962).

Case Western Reserve School of Medicine (Cleveland) (1958-1962):

Conducted four years of psychopharmacology lab research with controlled animal trials supported by NIMH grant, resulting in first two published papers in psychopharmacology.

Special four-year individual tutorial with pediatrician Benjamin Spock, M.D.

Diplomat, National Board of Medical Examiners (1963):

Highest grade in country (99%) on psychiatry portion of boards used to qualify for medical licenses.

Massachusetts Mental Health Center (Boston) (1963-64):

First Year Resident in Psychiatry at the main Harvard teaching hospital.

Teaching Fellow at Harvard Medical School.

State University of New York Upstate Medical Center (Syracuse) (1962-63, 1964-66):

Intern in Mixed Medicine and Psychiatry.

Second and Third Year Resident and Teaching Assistant in Psychiatry.

National Institute of Mental Health (NIMH) and U. S. Public Health Service Officer

(Charlottesville, VA and Bethesda, MD) (1966-68):

Full-time NIMH Consultant in Building and Staffing Community Mental Health Centers (1966-67).

Full-time NIMH Consultant in Mental Health and Education (1967-68).

University of Maryland (1968-1970):

Faculty, courses in counseling department.

Washington School of Psychiatry (1968-1972):

Faculty, courses for school counselors.

George Mason University (1990-96):

Adjunct Professor of Conflict Analysis and Resolution, courses on brain and behavior.

Johns Hopkins University (1996-99):

Faculty Associate in the Department of Counseling and Human Services, courses including psychopharmacology and diagnosis in psychiatry.

II. HIGHLIGHTS OF PROFESSIONAL ACTIVITIES:

Private Practice of Psychiatry, Washington, DC and Bethesda, MD. (1968-2002):

Full-time private practice with individuals, families, and children.

Subspecialty clinical psychopharmacology and the drug approval process.

Private Practice of Psychiatry, Ithaca, New York. (2003-present):

In November 2002, all of my professional activities moved to Ithaca, New York.

Founder and Director, International Center for the Study of Psychiatry and Psychology (1972-2002) and Director Emeritus (2002-present):

Founded and directed reform organization called "the conscience of psychiatry" including a professional peer-reviewed journal, annual scientific meetings and two thousand members.

Editor-in-Chief (1998-2002) and Founding Editor and Consultant (2002-present) of *Ethical Human Sciences and Services: An International Journal of Critical Inquiry.*

Founded and edited a peer-reviewed journal with 40 contributing editors published by Springer Publishing Company.

Editorial Consultant (mostly current):

International Journal of Risk and Safety in Medicine

The Psychotherapy Patient

Journal of Critical Psychology, Counselling and Psychotherapy: Journal of the Psychology and Psychotherapy Association

The Humanistic Psychologist

Journal of Mind and Behavior

Hospital and Community Psychiatry (reviewer in past)

Scientific Presenter at Conferences, Grand Rounds, Universities:

Hundreds of invited scientific presentations on psychopharmacology, shock treatment, psychosurgery, psychotherapy, and legal issues, including to the National Institutes of Health (NIH) Consensus Development Conferences on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder (November 1998); the NIH Consensus Development Conference on Electroconvulsive Therapy (1985); National Institutes of Health Panel on NIH Research on Anti-social, Aggressive and Violence-related Behaviors and Their Consequences (1994); National Institute of Mental Health (NIMH) Guest Speakers Program; U.S. House of Representatives Committee on Education (September 2000); American Psychiatric Association; NIH Institute on Hospital and Community Psychiatry; American Psychological Association; American Orthopsychiatry Association; American Autism Society; American Association for the Advancement of Science; American Counseling Association, Connecticut Psychiatric Society Residents Program, Harvard University School of Education Special Lecture; Georgetown University School of Medicine Department of Pharmacology; New Jersey Medical School Department of Psychiatry Annual Medical Forum; Walter Reed Army Hospital Psychiatric Residency Program; National Naval Medical Center; Metropolitan Hospital Center/New York Medical College Department of Psychiatry; Manhattan State Hospital (New York City) Grand Rounds; Spring Grove Hospital (Maryland) CME Credit Seminars; Chestnut Lodge Hospital Case Conference; St. Elizabeths Hospital Grand Rounds and Seminars (Washington, DC); Regents College of Psychotherapy and Counseling (London); Institute for Genetics (Cologne); Royal Ottawa Hospital Grand Rounds (Canada); MIND of Great Britain; University of Sheffield Department of Psychiatry (England).

Special Presentations and Advanced Training Courses related to Clinical Psychopharmacology:

I have presented at and/or attended a number of lengthy several-day-long training workshops on the drug approval process that dealt with labeling, often in great depth. The following seminars, including several at which I made presentations, dealt extensively with adverse drug reactions, drug development, labeling and related processes:

(1) "Regulatory Training Course I: IND [Investigative New Drug] Phase."

A course in how drug companies develop an IND for the FDA in accordance with FDA statutes, regulations, and guidelines. DIA (Drug Information Association). Bethesda, Maryland, February 26-28, 1996.

(2) "Future development of neuroleptic medications: A report to the FDA." This was a report to an FDA Meeting of the Psychopharmacologic Drugs Advisory Committee concerning labeling issues and the future development of neuroleptic medications. It was published as "Future development of neuroleptic medications: A report to the FDA" in the Rights Tenet (Newsletter of the National Association for Rights Protection and Advocacy) Fall 1995.

(3) "Regulatory Training Course II: Marketing Application & Post Approval Phase." A course in how drug companies develop an NDA [New Drug Application], as well as post-approval activities, in accordance with FDA statutes, regulations, and guidelines. DIA (Drug Information Association), Bethesda, Maryland, March 27-29, 1996.

(4) "Clinical Therapeutics and the Recognition of Drug-Induced Disease: How Health Care Professionals and the FDA Can Work Together to Reduce the Risks of Adverse Drug Events." A workshop focused on the spontaneous reporting system presented by the Center for Drug Evaluation and Research (CDER) of the FDA, Georgetown University School of Medicine, Washington DC, June 10, 1994.

(5) "The Application of GCP [Good Clinical Practices] for Study Site Coordinators and Business Administrators." Described as "a comprehensive, practical overview of the responsibilities of the investigator, the clinical study coordinator assisting the investigator, and the sponsor in the conduct of a clinical trial" for FDA approval of a drug. DIA (Drug Information Association), Philadelphia, December 11-13, 1995.

(6) "Pharmaceutical Industry Crisis Management Workshop." Purpose described as "to develop the participants knowledge of the fundamental elements of crises and crisis management in the pharmaceutical industry." Initial day covered handling of a variety of issues, including New Drug Applications (NDAs), FDA regulations and industry relations, recalls, adverse drug event reporting, and clinical trial standards. DIA (Drug

Information Association), Washington, DC, December 4, 2000.

(7) "Ritalin Litigation." Described as "The medical and legal roadmap to trying or defending your Ritalin suit successfully," including presentations on stimulant drug treatment, ADHD, and the role of the FDA and DEA in monitoring industry activities. I presented on "The science behind the lawsuits" (including labeling issues) and also attended. The American Conference Institute, New York City, March 29, 2001.

(8) "Emerging Drug Litigation Conference." One-half day on class action suits at which I presented on "The Science and Medicine of Ritalin" (including labeling issues) and also attended. Mealey's (Lexis/Nexis). New Orleans, May 17, 2001.

(9) "Adverse Effects of SSRI Medications: A Medical Legal Conference." Labeling was a key issue at this conference focused on product liability. I presented on "Adverse Psychiatric Effects of SSRI Antidepressants" (including labeling issues) and attended conference. Extant Medical Legal Consulting. Philadelphia, October 4-5, 2002.

(10) "SSRI-Induced Stimulation, Suicidality and Violence in Children and Adults." These were public presentations to two FDA Advisory Committee meetings on modifying the labeling for SSRI-induced suicidality in children. Each meeting involved the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee. I summarized evidence for a stimulant syndrome that causes suicidality and violence that should be included in the label. The label changes later adopted by the FDA closely parallel my suggestions in my presentations and publications. Bethesda, Maryland, February 2, 2004 and September 13, 2004.

(11) "Anti-Depressant Suicidality and Violence: More about Deception than Science. Observations Made at the FDA Hearings Press Conference, sponsored by the Alliance for Human Research protection (AHRP)." I address issues surrounding what kind of material gets into FDA-approved labels, including the limitations of that data. Other presenters discussed related issues. Bethesda, Maryland, September 14, 2004.

Medical Expert and Researcher:

I have testified in many cases in past 25 years including criminal, malpractice, product liability and class action, often involving psychopharmacology, including neuroleptic-induced tardive dyskinesia and SSRI-induced violence and suicide.

Some of the suits in which I have been involved, and some of research I have published, resulted in changes being made in the FDA-approved labels for

neuroleptics and SSRI antidepressants.

A few highlights include:

(1) Medical expert in *Kaimowitz v. Department of Mental Health*, Wayne County, Michigan (1973). The three-judge panel followed my testimony in an opinion that helped to stop lobotomy and psychosurgery in the state and federal facilities around the country.

(2) Medical expert for the 100 or more combined Prozac product liability suits (1992-1994) against Eli Lilly, including the famous Wesbecker trial (Fentress et al.) that the drug company secretly settled in a controversial manipulation of the court system.

(3) Medical expert and consultant in many tardive dyskinesia malpractice and product liability suits.

(4) Medical expert in numerous criminal cases with defenses based on involuntary intoxication with psychiatric drugs.

(5) Invited Scientific Presenter on adverse drug effects in children at the November 1998 National Institutes of Health (NIH) Consensus Development Conference on the Diagnosis and Treatment of Attention Deficit Disorder.

(6) Medical consultant for the FAA (Federal Aviation Agency) concerning effects of SSRIs on pilots (1998-2000).

(7) Testimony before the Food and Drug Administration (FDA) on the dangers of SSRI antidepressants in children (February 2004). The published opinion of the FDA panel closely paralleled my testimony and publications about the overall risk of stimulation (activation) with the potential for agitation, violence and suicide.

Memberships:

American Psychiatric Association (Life Member)
American Orthopsychiatry Association (Fellow)
Canadian Psychiatric Association
Royal Society of Medicine
Regulatory Affairs Professionals Society (RAPS)
Drug Information Association (DIA)
American Psychological Association
World Association of Medical Editors

Medical Licenses:

New York State, Washington, D.C., Maryland, and Virginia.

Publications:

19 professional books and more than 30 peer-reviewed journal articles, many in the area of psychopharmacology (see below for details).

III. PROFESSIONAL BOOKS (1962-present):

1. College Students in a Mental Hospital: Contribution to the Social Rehabilitation of the Mentally Ill (New York, Grune & Stratton, 1962) (jointly authored by Carter Umbarger, James Dalsimer, Andrew Morrison, and Peter Breggin).
2. Electroshock: Its Brain-Disabling Effects (Springer, NY, 1979).
3. The Psychology of Freedom: Liberty and Love as a Way of Life Buffalo, Prometheus Books, 1980.
4. Psychiatric Drugs: Hazards to the Brain (Springer, NY, 1983).
5. Toxic Psychiatry (St. Martin's, NY, 1991).
6. Beyond Conflict (St. Martin's, NY, 1992).
7. Talking Back to Prozac (with Ginger Breggin) (St. Martin's, NY, 1994).
8. The War Against Children (with Ginger Breggin) (St. Martin's, NY, 1994).
9. Psychosocial Approaches to Deeply Disturbed Persons (senior editor) (Haworth Press, NY, 1996).
10. Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock and the Role of the FDA (Springer, NY, 1997).
11. The Heart of Being Helpful: Empathy and the Creation of a Healing Presence (Springer, NY, 1997).
12. Talking Back To Ritalin (Common Courage Press, ME, 1998).
13. The War Against Children of Color: Psychiatry Targets Inner City Children. (Common Courage Press, ME, 1998) (with G. Breggin) Revision and update of The War Against Children.
14. Your Drug May Be Your Problem: How and Why To Stop Taking Psychiatric Medications. (Perseus Books, Cambridge, MA, 1999) (Co-authored by David Cohen, Ph.D.).
15. Reclaiming Our Children: A Healing Solution to a Nation in Crisis. (Perseus Books, Cambridge, MA, 2,000).
16. Talking Back to Ritalin, Revised Edition. (Perseus Books, Cambridge, MA,

2001).

17. The Antidepressant Fact book. (Perseus Books, Cambridge, MA, 2001)

18. Dimensions of Empathic Therapy (jointly co-edited by Ginger Breggin and Fred Bemak) (Springer, NY, 2002).

19. The Ritalin Fact Book. (Perseus Books, Cambridge, MA, 2002).

IV. PEER-REVIEWED PUBLICATIONS (1964-present):

1. "The Psychophysiology of Anxiety." Journal of Nervous Mental Diseases 139:558-568, 1964.

2. "Coercion of Voluntary Patients in an Open Hospital." Archives of General Psychiatry 10:173-181, 1964. Reprinted with a new introduction in Edwards, R.B. (ed): Psychiatry and Ethics. Buffalo, Prometheus Books, 1982, and in Edwards, R.B. (ed): Ethics of Psychiatry. Amherst, New York, Prometheus Books, 1997.

3. "The Sedative-like Effect of Epinephrine." Archives of General Psychiatry 12:255-259, 1965.

4. "Psychotherapy as Applied Ethics." Psychiatry 34:59-75, 1971.

5. "Therapy as Applied Utopian Politics." Mental Health and Society 1:129-146, 1974.

6. "Psychiatry and Psychotherapy as Political Processes." American Journal of Psychotherapy 29:369-382, 1975.

7. "Madness is a Failure of Free Will; Therapy Too Often Encourages It." Psychiatric Quarterly 53:61-68, 1981. Originally published (in French) in Verdiglione A (ed): La Folie Dans La Psychoanalyse. Paris, Payot, 1977.

8. "Electroshock Therapy and Brain Damage: The Acute Organic Brain Syndrome as Treatment." Behavior and Brain Sciences 7:24-25, 1984

9. "Neuropathology and Cognitive Dysfunction from ECT." Psychopharmacology Bulletin 22:476-479, 1986.

10. "Ellettroshock: Tra Rischioiatrogeno e Mito Terapeutico." (P. Breggin and G. de Girolamo) Quaderni Italiani di Psichiatria 6:497-540, 1987.

11. "The Three Dynamics of Human Progress: A Unified Theory Applicable to Individuals, Institutions and Society." Review of Existential Psychology and Psychiatry 21:(Nos. 1-3)97-123, 1988-89.

12. "Precious the Crow." Voices (Journal of the American Academy of Psychotherapists) 23:32-42, Summer 1987.
13. "Brain Damage, Dementia and Persistent Cognitive Dysfunction Associated with Neuroleptic Drugs: Evidence, Etiology, Implications." Journal of Mind Behavior 11:425-464, 1990.
14. "Psychotherapy in the Shadow of the Psycho-Pharmaceutical Complex," Voices (journal of the American Academy of Psychotherapists) 27:15-21, 1991
15. "A Case of Fluoxetine-induced Stimulant Side Effects with Suicidal Ideation Associated with a Possible Withdrawal Syndrome ("Crashing")." International Journal of Risk & Safety in Medicine 3:325-328, 1992
16. "Parallels Between Neuroleptic Effects and Lethargic Encephalitis: The Production of Dyskinesias and Cognitive disorders." Brain and Cognition 23:8-27, 1993.
17. "A Biomedical Programme for Urban Violence Control in the US: The Dangers of Psychiatric Social Control." (Peter Breggin and Ginger Ross Breggin). Changes: An International Journal of Psychology and Psychotherapy 11, No. 1 (March):59-71, 1993.
18. "Psychiatry's Role in the Holocaust." International Journal of Risk and Safety in Medicine 4:133-148, 1993. Adapted from a paper delivered at "Medical Science Without Compassion" in Cologne, Germany and published in the conference proceedings.
19. "Should the Use of Neuroleptics Be Severely Limited?" Changes: An International Journal of Psychology and Psychotherapy 14:62-66 March 1996.
20. "The Hazards of Treating 'Attention-Deficit/Hyperactivity Disorder' with Methylphenidate (Ritalin)" (coauthored by Ginger Breggin) Journal of College Student Psychotherapy 10:55-72, 1996.
21. "Psychotherapy in Emotional Crises without Resort to Psychiatric Medication." The Humanistic Psychologist 25:2-14, 1998.
22. "Analysis of Adverse Behavioral Effects of Benzodiazepines with a Discussion of Drawing Scientific Conclusions from the FDA's Spontaneous Reporting System." Journal of Mind and Behavior 19:21-50, 1998.
23. "Electroshock: Scientific, ethical, and political issues." International Journal of Risk & Safety In Medicine 11:5-40, 1998.
24. "Psychostimulants in the treatment of children diagnosed with ADHD: Part

I—Acute risks and psychological effects." Ethical Human Sciences and Services 1:13-33, 1999.

25. "Psychostimulants in the treatment of children diagnosed with ADHD: Part II—Adverse effects on brain and behavior." Ethical Human Sciences and Services 1:213-241, 1999.

26. "Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action." International Journal of Risk and Safety in Medicine, 12 (1), 3-35, 1999. (Simultaneously published version of #'s 24 and 25)

27. "Empathic self-transformation and love in individual and family therapy." Humanistic Psychologist, 27:267-282, 1999.

28. "What psychologists and psychotherapists need to know about ADHD and stimulants." Changes: An International Journal of Psychology and Psychotherapy 18:13-23, Spring 2000

29. "The NIMH multimodal study of treatment for attention-deficit/hyperactivity disorder: A critical analysis." International Journal of Risk and Safety in Medicine 13:15-22, 2000

30. "Empowering social work in the era of biological psychiatry." (2001) [The annual Ephraim Lisansky lecture of the University of Maryland School of Social Work.] Ethical Human Sciences and Services 3:197-206.

31. "Fluvoxamine as a cause of stimulation, mania, and aggression with a critical analysis of the FDA-approved label." International Journal of Risk and Safety in Medicine, 14: 71-86, 2002.

32. "Psychopharmacology and human values." Journal of Humanistic Psychology, 43: 34-49, 2003.

33. "Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis." Ethical Human Sciences and Services 5:225-246, 2003. Simultaneously published in the International Journal of Risk and Safety in Medicine, 16, 31-49, 2003/2004.

34. "Recent U.S., Canadian and British regulatory agency actions concerning antidepressant-induced harm to self and others: A review and analysis." Ethical Human Psychology and Psychiatry, 7, 7-22, 2005. Simultaneously published in the International Journal of Risk and Safety in Medicine, 16, 247-259, 2005.

35. "Recent regulatory changes in antidepressant labels: Implications for activation (stimulation) in clinical practice." Primary Psychiatry, 13, 57-60, 2006.